Afleveringen
-
Join host Julia Cartwright as she unravels the surprising truth behind Ozempic and Wegovy—two names, one molecule, and a whole lot of confusion. Discover the dosing differences, insurance battles, and what your doctor really considers before writing that prescription.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI. -
Julia Cartwright examines what doctors really consider when prescribing Ozempic versus Wegovy—the same semaglutide molecule with different FDA approvals, dosing, and insurance coverage. From BMI thresholds and prior authorizations to off-label use and cost barriers, this episode unpacks the complex medical and bureaucratic factors shaping your prescription in ways you never realized.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI. -
Zijn er afleveringen die ontbreken?
-
Join host Julia Cartwright as she explores why Ozempic and Wegovy—though both semaglutide—produce dramatically different results. Through FDA approvals, clinical trials, and dosing science from 2 mg to 7.2 mg, discover how tiny differences transform blood sugar management into life-changing weight loss.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI. -
Join host Julia Cartwright as she unravels how one molecule—semaglutide—became two FDA-approved drugs with distinct missions. We explore the clinical trials, regulatory decisions, and dosing strategies that split Ozempic (for diabetes) from Wegovy (for weight management), revealing why this distinction matters for patients, coverage, and modern medicine's evolving approach to treating chronic disease.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI.
